Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
H2R Thank you. I agree.
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
GlobeNewswire - 21 minutes ago Investment News
Email Facebook. Twitter. LinkedIn. Print
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. ( OTLK ) , a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed its previously announced private placement with Syntone Ventures, LLC, an existing stockholder, for upfront gross proceeds of approximately $5.0 million from the issuance and sale of shares of the Company’s common stock and accompanying warrants, before deducting offering expenses. In addition, Outlook Therapeutics ( OTLK ) has the potential to receive additional gross proceeds of up to $8 million upon the full cash exercise of the warrants issued in the private placement, before deducting offering expenses.
About the Private Placement
Pursuant to the securities purchase agreement entered into on January 24, 2024, Outlook Therapeutics ( OTLK ) issued to Syntone an aggregate of 714,286 shares of common stock and accompanying warrants to purchase an aggregate of 1,071,429 shares of common stock, at a price of $7.00 per share and accompanying warrant to purchase one and one-half shares of common stock. The warrants have an exercise price of $7.70 per share and are exercisable only for cash until their expiration on the fifth anniversary of the issuance date. The warrants include a feature that allows Outlook Therapeutics to require Syntone to cash exercise the warrants if certain stock price and milestone conditions are met.
All of the securities in the private placement were offered by the Company.
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
GlobeNewswire - 5:10 PM ET 3/18/2024 Investment News
ISELIN, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. ( OTLK ) , a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed its previously announced private placement, for upfront gross proceeds of approximately $60 million from the issuance and sale of shares of the Company’s common stock and accompanying warrants, before deducting placement agent fees and offering expenses. Outlook Therapeutics has the potential to receive additional gross proceeds of up to $99 million upon the full cash exercise of the warrants issued in the private placement, before deducting placement agent fees and offering expenses.
The private placement was led by Great Point Partners, LLC, with participation from existing investor GMS Ventures as well as new investors Altium Capital, Armistice Capital, Caligan Partners LP, Schonfeld Strategic Advisors, Sphera Healthcare, Velan Capital, Woodline Partners LP, and an undisclosed life sciences dedicated investor.
BofA Securities and BTIG acted as co-placement agents in connection with the financing.
Per Fidelity:
BY Benzinga
— 6:18 AM ET 07/17/2023
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics NASDAQ:AXSM with a Buy and lowers the price target from $200 to $190.
Sawston Commercial License
Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility
BY PR Newswire
— 7:58 PM ET 03/20/2023
One of the First UK Licenses for Commercial Manufacturing of Cell Therapy Products;
Allows Global Delivery of the Products
BETHESDA, Md., March 20, 2023 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, and Advent BioServices, a leading contract development and manufacturing organization (CDMO) based in the UK, jointly announce that a MIA license has been approved and issued by the Medicines and Healthcare Products Regulatory Agency (MHRA) for commercial manufacturing of cell therapy products at the GMP facility in Sawston, U.K.
Northwest Biotherapeutics Logo.
This MIA is one of the first licenses for commercial manufacturing of cell therapy products in the U.K. To the companies' knowledge, there are only two other such licenses, one of which was just granted as well.
This license is the culmination of more than 3 years' work, including development of the facility, the teams of specialized personnel, the Standard Operating Procedures (SOPs) and systems, well over 1,650 regulatory documents, and a successful operating history under the initial manufacturing licenses previously obtained to produce cell therapies in the Sawston facility for clinical trials and compassionate use. All of this work was carried out by Advent BioServices under contract with NW Bio.
Under this commercial manufacturing license, cell therapy products manufactured in the Sawston facility may be exported globally. Products (e.g., immune cells) may also be imported into the U.K. for production or release of cell therapy products under the facility's licenses.
Linda Powers, CEO of NW Bio, commented, "We are very excited to reach this major milestone, as it is an essential step towards submission of our application for regulatory approval of our lead product, DCVax®-L. It is especially exciting to be able to operate globally from this base in the U.K."
Dr. Mike Scott, President of Advent BioServices, commented, "It is always challenging to be one of the trailblazers. The field of personalised cell-based immunotherapy is rapidly evolving and we are collectively navigating our way through the regulatory landscape. We are therefore thrilled that the extensive preparatory work undertaken by our skilled and dedicated team has met the extremely high standards set for this commercial level of manufacturing license."
About Northwest Biotherapeutics (NWBO)
Northwest Biotherapeutics (NWBO) is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." This Phase III trial has been completed, and the results have been presented in scientific meetings and published in JAMA Oncology. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
About Advent BioServices
Advent BioServices is a contract development and manufacturing organization (CDMO) based in Sawston, U.K. The Company operates the 88,000 square foot GMP facility in Sawston, which includes a large, HTA licensed, cryostorage facility capable of storing several million vials of tissues and cells, and includes capabilities for all stages of cell therapy development and production. During the past three-plus years, the Company has recruited staff members with a wide spectrum of specialist skills in the cell therapy space. The Process Development and QC teams provide significant expertise in complex assay development, GMP manufacturing, product release and GMP-related monitoring which has underpinned the work leading to MHRA licensing for commercial manufacturing, as well as the prior licenses for manufacturing for clinical trials and compassionate use (Specials).
sounds reasonable
Are you referring to their filing for permission to sell up to $250 million in added shares? Showed up in my brokerage feed this morning.
Actually a good move to sell half/keep half. I did likewise, have more than my cost back in the (now free) shares I kept. I've been burned enough times by being greedy.
Print Format
Change Text Size:
Default text sizeA Larger text sizeA Largest text sizeA
Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
BY GlobeNewswire
— 7:00 AM ET 07/28/2022
Axsome to host conference call and webcast on Tuesday, August 9, 2022 at 8:00 AM Eastern Time
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM) , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter of 2022 on Tuesday, August 9, 2022 before the opening of the U.S. financial markets. Axsome’s management team will host a conference call at 8:00 AM Eastern Time on August 9, 2022 to discuss these results and provide a business update.
To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic). A live webcast of the conference call can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at www.axsome.com. A recording of the conference call will be available on the Company’s website for approximately 30 days following the live event.
Good man!
After the drop, I got in at $23. Hoping these accretive gains continue. Wishing I had purchased more shares at that price point.
There is a SA article: BioLineRx: A Top Candidate For A Takeover Before 2022 Ends
Yes, agreed. It is however one of those carefully constructed short theses which, while it won't influence a long who has done extensive DD, can easily influence someone who is in this casually. It clearly did not move the markets much this morning.
Short-oriented blurb on SA today, based on a detailed short piece by some entity called JCap. Can't post it but there was a link in the SA piece.
Congrats. I should have sold more of my shares when I could early on. Plan to buy back the shares I did sell.
13G filing, which I think relates to the earlier $25MM stock placement:
http://archive.fast-edgar.com/20210226/AWZGJ22CW222R2C2222M22Z2FSTRZ22I9232
Bull, what price levels does your model show?
Would not be surprised by a buyout. They already have a commercial relationship with nestle for adding NR to nestle products. Time will tell. No rush on my part.
I myself am an accredited investor, most of the time investing in not-yet-listed non-public companies. So the buyers are willing to wait a while and I'm sure there were some non-publicized understandings about what conditions have to be met before the non-public shares have their (probably) section 144 restriction removed. They clearly have confidence in CDXC.
I've been going thru weeks of rigamarole getting my restrictions lifted on another stock.
Thank you for refreshing my aging memory.
As summarized by MT newswire:
ChromaDex Shares Rally After COVID-19 Patients on Nutrient Recover Faster in Study
BY MT Newswires
— 3:12 PM ET 02/25/2021
03:12 PM EST, 02/25/2021 (MT Newswires) -- ChromaDex ( CDXC ) shares jumped more than 120% Thursday after a late-stage study showed that the addition of a nutritional protocol including nicotinamide riboside helped speed up the recovery of mild-to-moderate COVID-19 patients.
The nutritional addition reduced recovery time and improved liver health while lowering inflammation, according to the trial results published on medRxiv. ChromaDex ( CDXC
Loading... Loading...
) markets Tru Niagen, a cellular nutrient used to raise nicotinamide levels.
Separately, the company said it has raised $25 million after selling some 3.85 million shares to institutional investors at $6.50 each. It plans to use the proceeds to grow the Tru Niagen brand and for general corporate purposes.
Price: 22.55, Change: +12.81, Percent Change: +131.52
Whichever cause, my account balances are loving this.
Good luck, Infinity. I'm a L-T holder. Cost basis 2-3.40 depending on the account. As you can tell, patience is my long suit; not trading. I assume you are attracted to the action.
Thanks. We shall see at some point. SP increase could also be a buy out.
Even more insane SP. Up 51 percent, with volume 30+X daily average.
Don't hold me to spelling, but Patrick Soong Shin?
Clearly, with the surge in SP and the volume after 1.5 hours of 10X the daily average over the last 90 days, someone thinks they know something. I believe Dr. Frost still owns a major number of shares.
Why the gap up today (Feb 25, 2021)?
Per an 8k today:
Thanks Trend and Ejob for keeping things updated while I was out.
I meant to say "keeping posting" rather than just "keeping."
Thanks guys for keeping while I had an extended trip. I also requested IHub change our symbol back to BIVI, so we can get price/volume info on this page.
Thanks guys for keeping the information up to date. Been traveling out of the country.
Sounds good.
Price getting to a tempting level again.
Clearly, I am not going to invest there.
You can still buy whatever booze you wish. PLMK what you find as an investment.
Yes, I recall that Elliot Management - supposedly working as an "activist investor" - had insisted they do a buyback. Guess the slope in the chart for the last year reflects their cracking the whip. They may also tender their shares in the offer. All just IMO.
Understand completely (your position, not the French taxation).